Intrexon

Intrexon has raised $709 million across multiple funding rounds, with notable raises including $450K Post-IPO in Feb 2015 and two additional $4.25M Post-IPO rounds in 2016. Founded in 1998, the company focuses on developing gene-based therapeutics for oncology, cardiology, and neurological disorders. With strong backing from Third Security and other strategic investors, funding has supported its R&D programs, gene-therapy platforms, and clinical pipelines. Intrexon’s investments have enabled expansion into synthetic biology, advanced genetic engineering, and precision medicine as it continues exploring next-generation human therapeutics.